Table 3 Summary of absolute net benefit statistics
From: Cost-utility of tiotropium in patients with severe asthma
ICS + LABA | Tiotropium + ICS + LABA | |
|---|---|---|
Mean discounted lifetime QALYs | 0.1714 | 0.1732 |
Mean discounted lifetime costs (U$) | 101 | 96 |
Expected net benefit at US$ 5180 per QALY | 786 | 800 |
95% lower CI (on costs scale) | 390 | 357 |
95% upper CI (on costs scale) | 1070 | 1111 |
Expected net benefit on effects scale | 0.1518 | 0.1545 |
95% lower CI (on effects scale) | 0.0754 | 0.0690 |
95% upper CI (on effects scale) | 0.2066 | 0.2147 |